CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

yahoo_finance
Original article

Summit Therapeutics (SMMT) Is Up 7.3% After $2 Billion AstraZeneca Partnership and Trial Collaboration

PartnershipPositive
AI Analysis

Summary

AstraZeneca and Summit Therapeutics announced a $2 billion partnership and trial collaboration, resulting in a 7.3% increase in Summit's stock price.

Importance:7/10
Sentiment:
0.80
partnershipcollaborationclinical_trialstock_movement
Related Companies

Read the original article

Published by yahoo_finance on October 2, 2026 11:06 PM

Read Original